The introduction of antibodies against programmed cell death protein-1 (PD-1) and its ligand (PD-L1), a crucial axis involved in the immune surveillance, has prompted encouraging results in the treatment of advanced non-small cell lung carcinoma (NSCLC), although only a minority of patients show clinical response [1]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.